PARDES BIOSCIENCES, INC. for PARDES BIOSCIENCES, INC.
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Funding for COVID-19 Therapeutics, specifically Oral Antivirals. Advance Purchase Agreements Strategic National Stockpile Pandemic Preparedness
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MARTIN New | Principal Associate Commissioner, FDA Legislative Director, Sen. Tom Cotton |
Health Issues HCR
Funding for COVID-19 Therapeutics, specifically Oral Antivirals. Advance Purchase Agreements Strategic National Stockpile Pandemic Preparedness
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MARTIN New | Principal Associate Commissioner, FDA Legislative Director, Sen. Tom Cotton |
Medical/Disease Research/Clinical Labs MED
Funding for COVID-19 Therapeutics, specifically Oral Antivirals. Advance Purchase Agreements Strategic National Stockpile Pandemic Preparedness
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MARTIN New | Principal Associate Commissioner, FDA Legislative Director, Sen. Tom Cotton |
Medicare/Medicaid MMM
Funding for COVID-19 Therapeutics, specifically Oral Antivirals. Advance Purchase Agreements Strategic National Stockpile Pandemic Preparedness
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MARTIN New | Principal Associate Commissioner, FDA Legislative Director, Sen. Tom Cotton |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.